Key facts
- This page summarizes RTW INVESTMENTS, LP's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
- 9 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 23 Sep 2025, 16:21.
RTW INVESTMENTS, LP - 19 Sep 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)
- Reporting relationship
- Director, Other*, 10%+ Owner
- Issuer ticker
- RCKT
- Reported as of
- 19 Sep 2025
- Net transaction value
- +$38,450,516
- SEC form
- 4
- Accepted by SEC
- 23 Sep 2025, 16:21:23 UTC
- Prior SEC filing
- 06 Aug 2025
- Next SEC filing
- 07 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- RTW Investments, LP, By /s/ Roderick Wong, M.D., Managing Partner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
RTW INVESTMENTS, LP filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 23 Sep 2025.
Change
- Previous filing in this sequence was filed on 06 Aug 2025.
- Current net transaction value: +$38,450,516.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (2)
CIK 0001493215
Primary reporting owner
RTW INVESTMENTS, LP
- Relationship
- Director, Other*, 10%+ Owner
- Address
- 40 10TH AVENUE, FLOOR 7, NEW YORK
- Signature
- RTW Investments, LP, By /s/ Roderick Wong, M.D., Managing Partner
- Signature date
- 23 Sep 2025
CIK 0001493280
WONG RODERICK
- Relationship
- Director, Other*, 10%+ Owner
- Address
- C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, FLOOR 7, NEW YORK
- Signature
- Roderick Wong, By /s/ Roderick Wong, M.D.
- Signature date
- 23 Sep 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RCKT
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $40,032,400
- Shares
- +1,000,000
- Change %
- +5.5%
- Price
- $40.03
- Shares after
- 19,188,457
- Date
- 19 Sep 2025
- Ownership
- See footnote
- Footnotes
- F1, F2
RCKT
transaction
Common Stock
Other
- Transaction value
- $3,105,000
- Shares
- -1,000,000
- Change %
- -5.2%
- Price
- $3.10
- Shares after
- 18,188,457
- Date
- 19 Sep 2025
- Ownership
- See footnote
- Footnotes
- F1, F2
RCKT
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $782,756
- Shares
- +41,000
- Change %
- +0.23%
- Price
- $19.09
- Shares after
- 18,229,457
- Date
- 19 Sep 2025
- Ownership
- See footnote
- Footnotes
- F2, F3
RCKT
transaction
Common Stock
Other
- Transaction value
- $127,305
- Shares
- -41,000
- Change %
- -0.22%
- Price
- $3.10
- Shares after
- 18,188,457
- Date
- 19 Sep 2025
- Ownership
- See footnote
- Footnotes
- F2, F3
RCKT
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $1,050,861
- Shares
- +59,000
- Change %
- +0.32%
- Price
- $17.81
- Shares after
- 18,247,457
- Date
- 19 Sep 2025
- Ownership
- See footnote
- Footnotes
- F2, F4
RCKT
transaction
Common Stock
Other
- Transaction value
- $183,195
- Shares
- -59,000
- Change %
- -0.32%
- Price
- $3.10
- Shares after
- 18,188,457
- Date
- 19 Sep 2025
- Ownership
- See footnote
- Footnotes
- F2, F4
RCKT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 47,667
- Date
- 19 Sep 2025
- Ownership
- Direct
- Footnotes
- F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RCKT
transaction
Derivative
Equity Swap (obligation to buy)
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- Shares
- -1
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 19 Sep 2025
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 1,000,000
- Exercise price
- $40.03
- Footnotes
- F1, F2
RCKT
transaction
Derivative
Equity Swap (obligation to buy)
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- Shares
- -1
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 19 Sep 2025
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 41,000
- Exercise price
- $19.09
- Footnotes
- F2, F3
RCKT
transaction
Derivative
Equity Swap (obligation to buy)
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- Shares
- -1
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 19 Sep 2025
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 59,000
- Exercise price
- $17.81
- Footnotes
- F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd. previously reported on the Forms 4 filed by the Reporting Persons on May 13, 2021 and April 5, 2023, expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change.
Footnote F2
This Form 4 is being filed by each of (i) RTW Investments, LP (the "Adviser") with respect to the securities held by certain investment funds managed by the Adviser (the "RTW Funds") and (ii) Roderick Wong, M.D. ("Dr. Wong"), who serves as the Managing Partner and Chief Investment Officer of the Adviser and who is a director of the Issuer and Chairman of the Issuer's Board of Directors.
Footnote F3
On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 22, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change.
Footnote F4
On September 19, 2025, the equity swap entered into by RTW Innovation Master Fund, Ltd previously reported on the Form 4 filed by the Reporting Persons on December 23, 2022 expired and settled in accordance with its terms. After the transaction reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change.
Footnote F5
Represents restricted stock units ("RSUs") held by Dr. Wong that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026.
SEC remarks
The Adviser may be deemed to be a director by deputization for purposes of Section 16 under the Securities Exchange Act of 1934 by virtue of the fact that each of Dr. Wong, Gotham Makker, who serves as a Partner and Head of Strategic Investments of the Adviser, and Piratip Pratumsuwan, who serves as Managing Director, Research Analyst of the Adviser, currently serves on the board of directors of the Issuer. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.